May 11, 2021
MedNous addressing multiple uses for Leyden Labs' nasal sprays
Last month, our CEO Koenraad Wiedhaup spoke with co-founder and editor of MedNous, Victoria English, about Leyden Labs. They discussed the development of our platform and portfolio of prophylactic nasal sprays that should protect people from infection with respiratory viruses, such as influenza and coronaviruses.
English also discusses how Leyden Labs' intranasal products could play an important role in preventing and managing future pandemics. Firstly, when a spray like this would be available from the start of a viral outbreak, people could protect themselves until efficacious vaccines are widely distributed. Additionally, at later stages of a pandemic when vaccines may have been developed, people may still be seeking additional protection. For instance, people with compromised immune systems for whom vaccines may not as effective can benefit from additional protection from Leyden Labs' nasal spray on top of the vaccine.
To read the full article, click here.
Published in the April 2021 edition of MedNous, a publication of Evernow Publishing Ltd.
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
Leyden Laboratories Co.
Boston Laboratory
201 Dexter Avenue
Watertown
MA 02472
United States
Leyden Labs, S.L.
Granada Office
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud
18016 Granada
Spain
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra
